[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657933":3},{"organization":4,"outcomesModule":7,"designInfo":87,"detailedDescription":90,"studyPopulation":91,"armGroups":92,"interventions":86,"overallOfficials":96,"centralContacts":101,"locations":86,"responsibleParty":107,"collaborators":86,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":86,"eligibilityCriteria":117,"healthyVolunteers":113,"sex":118,"minAge":86,"maxAge":119,"enrollmentInfo":120,"targetDuration":86,"studyType":123,"phases":86,"briefSummary":124,"conditions":125,"keywords":130,"overallStatus":135,"whyStopped":86,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":86},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":34,"otherOutcomes":86},[9,13,16,19,22,25,28,31],{"measure":10,"description":11,"timeFrame":12},"Prevalence of Neurocutaneous Syndromes Among Pediatric Neurology Patients","Proportion of children diagnosed with neurocutaneous syndromes among all patients attending the Pediatric Neurology Unit during the study period. Prevalence calculated as number of NCS cases divided by total number of pediatric neurology attendees during the same period.","Baseline",{"measure":14,"description":15,"timeFrame":12},"Distribution of Neurofibromatosis Type 1","Frequency and percentage of Neurofibromatosis type 1 among diagnosed neurocutaneous syndrome cases.",{"measure":17,"description":18,"timeFrame":12},"Distribution of Neurofibromatosis Type 2","Frequency and percentage of Neurofibromatosis type 2 among diagnosed neurocutaneous syndrome cases.",{"measure":20,"description":21,"timeFrame":12},"Distribution of Tuberous Sclerosis Complex","Frequency and percentage of Tuberous Sclerosis Complex among diagnosed neurocutaneous syndrome cases.",{"measure":23,"description":24,"timeFrame":12},"Distribution of Sturge-Weber Syndrome","Frequency and percentage of Sturge-Weber syndrome among diagnosed neurocutaneous syndrome cases.",{"measure":26,"description":27,"timeFrame":12},"Distribution of Von Hippel-Lindau Disease","Frequency and percentage of Von Hippel-Lindau disease among diagnosed neurocutaneous syndrome cases.",{"measure":29,"description":30,"timeFrame":12},"Distribution of Incontinentia Pigmenti","Frequency and percentage of Incontinentia Pigmenti among diagnosed neurocutaneous syndrome cases.",{"measure":32,"description":33,"timeFrame":12},"Distribution of Hypomelanosis of Ito","Frequency and percentage of Hypomelanosis of Ito among diagnosed neurocutaneous syndrome cases.",[35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80,83],{"measure":36,"description":37,"timeFrame":12},"Cutaneous Manifestations","Frequency and percentage of cutaneous manifestations among children with neurocutaneous syndromes, assessed by clinical examination.",{"measure":39,"description":40,"timeFrame":12},"Epilepsy","Frequency and percentage of epilepsy among children with neurocutaneous syndromes, assessed by clinical examination and EEG.",{"measure":42,"description":43,"timeFrame":12},"Developmental Delay","Frequency and percentage of developmental delay among children with neurocutaneous syndromes, assessed by clinical examination.",{"measure":45,"description":46,"timeFrame":12},"Intellectual Disability","Frequency and percentage of intellectual disability among children with neurocutaneous syndromes, assessed by clinical examination.",{"measure":48,"description":49,"timeFrame":12},"CNS Tumors","Frequency and percentage of CNS tumors among children with neurocutaneous syndromes, assessed by MRI.",{"measure":51,"description":52,"timeFrame":12},"Ophthalmological Manifestations","Frequency and percentage of ophthalmological manifestations among children with neurocutaneous syndromes, assessed by ophthalmological assessment.",{"measure":54,"description":55,"timeFrame":12},"Cardiovascular Manifestations","Frequency and percentage of cardiovascular manifestations among children with neurocutaneous syndromes, assessed by clinical examination.",{"measure":57,"description":58,"timeFrame":12},"Renal Manifestations","Frequency and percentage of renal manifestations among children with neurocutaneous syndromes, assessed by clinical examination.",{"measure":60,"description":61,"timeFrame":12},"Musculoskeletal Manifestations","Frequency and percentage of musculoskeletal manifestations among children with neurocutaneous syndromes, assessed by clinical examination.",{"measure":63,"description":64,"timeFrame":12},"Management Patterns - Antiepileptic Medications","Frequency and percentage of children with neurocutaneous syndromes receiving antiepileptic medications.",{"measure":66,"description":67,"timeFrame":12},"Management Patterns - mTOR Inhibitors","Frequency and percentage of children with neurocutaneous syndromes receiving mTOR inhibitors.",{"measure":69,"description":70,"timeFrame":12},"Management Patterns - Surgical Interventions","Frequency and percentage of children with neurocutaneous syndromes undergoing surgical interventions.",{"measure":72,"description":73,"timeFrame":12},"Management Patterns - Laser Therapy","Frequency and percentage of children with neurocutaneous syndromes receiving laser therapy.",{"measure":75,"description":76,"timeFrame":12},"Management Patterns - Physiotherapy","Frequency and percentage of children with neurocutaneous syndromes receiving physiotherapy.",{"measure":78,"description":79,"timeFrame":12},"Management Patterns - Occupational Therapy","Frequency and percentage of children with neurocutaneous syndromes receiving occupational therapy.",{"measure":81,"description":82,"timeFrame":12},"Management Patterns - Speech Therapy","Frequency and percentage of children with neurocutaneous syndromes receiving speech therapy.",{"measure":84,"description":85,"timeFrame":12},"Management Patterns - Multidisciplinary Follow-Up","Frequency and percentage of children with neurocutaneous syndromes receiving multidisciplinary follow-up care.",null,{"allocation":86,"interventionModel":86,"interventionModelDescription":86,"primaryPurpose":86,"observationalModel":88,"timePerspective":89,"maskingInfo":86},"CASE_ONLY","CROSS_SECTIONAL","Neurocutaneous syndromes are congenital multisystem disorders that mainly affect the skin, nervous system, and other organs. This observational study will include children from birth to 18 years diagnosed with neurocutaneous syndromes according to established clinical and\u002For genetic diagnostic criteria.\n\nData will be collected on demographic characteristics, clinical manifestations, laboratory and radiological findings, and current management practices.","Children aged from birth to 18 years diagnosed with neurocutaneous syndromes attending the Pediatric Neurology Unit (outpatient or inpatient) at Assiut University during the study period.",[93],{"label":94,"type":86,"description":95,"interventionNames":86},"Single cohort: Children with neurocutaneous syndromes","Children from birth to 18 years diagnosed with neurocutaneous syndromes who will undergo clinical, laboratory, radiological, and management assessment.",[97],{"name":98,"affiliation":99,"role":100},"Mohamed M El telawy, prof","pediatrics Department, Assiut University Hospitals","STUDY_CHAIR",[102],{"name":103,"role":104,"phone":105,"phoneExt":86,"email":106},"Eman M Zagloul, Resident","CONTACT","+20 11 51146456","emanmahmoudzagloul@gmail.com",{"type":108,"investigatorFullName":109,"investigatorTitle":110,"investigatorAffiliation":5,"oldNameTitle":86,"oldOrganization":86},"PRINCIPAL_INVESTIGATOR","Eman mahmoud zaghloul","Resident Physician","100657933","neurocutaneous-syndromes-in-children-prevalence-and-clinical-characteristics-100657933",false,"NCT07843823","Neurocutaneous Syndromes in Children: Prevalence and Clinical Characteristics","Prevalence, Clinical Characteristics, and Management of Neurocutaneous Syndromes in Children","Inclusion Criteria:\n\n* Age from birth to 18 years\n* Diagnosis of neurocutaneous syndrome according to established clinical and\u002For genetic diagnostic criteria\n* Written informed consent from parents or legal guardians\n\nExclusion Criteria\n\n* Uncertain diagnosis\n* Incomplete medical records\n* Refusal of parents or legal guardians to participate","ALL","18 Years",{"count":121,"type":122},100,"ESTIMATED","OBSERVATIONAL","This cross-sectional study aims to determine the prevalence, clinical characteristics, and management patterns of neurocutaneous syndromes among children attending the Pediatric Neurology Unit at Assiut University.",[126,127,128,129],"Sturge-Weber Syndrome","Neurocutaneous Syndromes","Neurofibromatoses","Tuberous Sclerosis",[127,131,132,133,126,134],"Phakomatoses","Neurofibromatosis type 1","Tuberous Sclerosis Complex","Assiut","NOT_YET_RECRUITING","2026-09-21",{"date":138,"type":139},"2026-09-28","ACTUAL",{"date":141,"type":122},"2026-09-20",{"date":143,"type":122},"2028-02-20",{"name":5,"class":6}]